Altamira Therapeutics (OTC:CYTOF) Gets USPTO Allowance for Key Patent
Innovative companies depend significantly on the success of their patents, and hence, the Altamira Therapeutics Inc. (OTC:CYTOF) stock could be the one to watch this morning. This past Friday the company was in focus after it made an announcement with regards to a allowance it got for a key product from the United States Patent and Trademark Office.
Patent Update
In the news release, the company announced that it had been awarded a Notice of Allowance for a patent related to the composition of its nasal spray Bentrio. The product in question had been commercialized and developed by Altamira Medica AG, its affiliate, for the prevention and treatment of allergic rhinitis. The patent claim from the company was related to the composition and ingredients of the proprietary formulation of the Bentrio product.
Implications
The patent would provide intellectual property protection to the formulation in the United States, the biggest market worldwide for ‘over the counter’ products meant for the treatment and relief of rhinitis. It goes without saying that the latest development could be seen as a major new positive for Altamira Therapeutics, and it may be a good time to add the stock to your watch lists.
Key Quote
“We are very pleased to have achieved this major milestone in the protection of our intellectual property around Bentrio,” commented Thomas Meyer, Altamira’s founder, chairman, and CEO. “Based on a drug-free and preservative-free formulation, Bentrio has demonstrated significant alleviation of the classic nasal symptoms of allergic rhinitis, including congestion, sneezing, itching, and rhinorrhea, as well as ocular symptoms. We look forward to making the product available in more and more countries, and in particular also to allergy sufferers in North America, through well-established partners in the consumer health space.”
Technicals
| +/- EMA(20) | 0.11 (+5.91%) |
| +/- SMA(50) | 0.12 (-2.92%) |
| +/- SMA(200) | 0.68 (-82.87%) |
| 5-Day Perf. | +15.35% |
| 1-Month Perf. | -1.44% |
| 3-Month Perf. | -74.66% |
| 6-Month Perf. | -86.91% |
| YTD Perf. | +5.43% |
| 1-Year Perf. | -93.8% |
| RSI(14) | 48.55 |
| ATR(14) | 0.03 |
| ADX(14) | 12.22 |
| Beta (5Y) | 0.60 |